Alnylam Pharmaceuticals (ALNY) Intangibles (2009 - 2012)
Alnylam Pharmaceuticals' (ALNY) quarterly Intangibles came in at $145000.0 in Q3 2012, down 54.4% YoY from $318000.0 in Q4 2011, and down 22.87% on a QoQ basis from $188000.0 in Q2 2012.
Alnylam Pharmaceuticals (ALNY) Intangibles (2009 - 2012) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 4 years of Intangibles data on file, last reported at $145000.0 in Q3 2012.
- Quarterly Intangibles fell 54.4% year-over-year to $145000.0 in Q3 2012, while the trailing twelve-month figure through Sep 2012 was $145000.0 (down 54.4% YoY) and the FY2011 annual result came in at $275000.0, down 38.62% from the prior year.
- Intangibles fell to $145000.0 in Q3 2012, from $188000.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $622000.0 in Q4 2009 to a low of $145000.0 in Q3 2012.
- A 4-year average of $365363.6 and a median of $361000.0 in 2011 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2010 — Intangibles decreased 27.97% — and 2012, when it plunged 54.4%.
- Tracing ALNY's Intangibles over 4 years: stood at $622000.0 in 2009, then declined by 27.97% to $448000.0 in 2010, then sank by 38.62% to $275000.0 in 2011, then slumped by 47.27% to $145000.0 in 2012.
- The last three Intangibles figures came in at $145000.0 (Q3 2012), $188000.0 (Q2 2012), and $231000.0 (Q1 2012), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 145,000.00 |
| Jun 30, 2012 | 188,000.00 |
| Mar 31, 2012 | 231,000.00 |
| Dec 31, 2011 | 275,000.00 |
| Sep 30, 2011 | 318,000.00 |
| Jun 30, 2011 | 361,000.00 |
| Mar 31, 2011 | 405,000.00 |
| Dec 31, 2010 | 448,000.00 |
| Sep 30, 2010 | 491,000.00 |
| Jun 30, 2010 | 535,000.00 |
| Dec 31, 2009 | 622,000.00 |